Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VIRxSYS, a privately-held biotechnology company with proprietary RNA payload and lentiviral vector delivery platform technologies, has been issued with two patents for its SMaRT (Spliceosome-Mediated RNA Trans-splicing) RNA platform technology by the US Patent and Trademark Office.
Subscribe to our email newsletter
US Patent No. 7,871,795 encompasses the use of the platform for trans-splicing into highly abundant gene transcripts to produce therapeutic products.
US Patent No. 7,879,321 covers the use of the platform for trans-splicing into highly abundant gene transcripts for antibody gene transfer and antibody production.
The SMaRT RNA platform technology targets gene transcripts in a cell, thereby repairing defective genes and reprogramming specific gene transcripts at the RNA level.
It also deletes any defective or unwanted parts of a gene transcript, and splices in new genetic information to create a healthy, functional protein or a totally different protein of therapeutic interest.
VIRxSYS president and CEO Riku Rautsola said with over 30 issued patents in the company’s robust SMaRT-based intellectual property portfolio, VIRxSYS is positioned to deliver on the promises of genetic medicine.
VIRxSYS plans to shortly initiate a non-human primate study aimed at testing the ability of its lead clinical candidate to raise serum apoA-I levels, which leads to an increase in HDL.